MITF

melanocyte inducing transcription factor, the group of Basic helix-loop-helix proteins

Basic information

Region (hg38): 3:69739456-69968336

Previous symbols: [ "WS2A", "WS2" ]

Links

ENSG00000187098NCBI:4286OMIM:156845HGNC:7105Uniprot:O75030AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Waardenburg syndrome type 2A (Strong), mode of inheritance: AD
  • ocular albinism with congenital sensorineural hearing loss (Definitive), mode of inheritance: AD
  • Tietz syndrome (Definitive), mode of inheritance: AD
  • Waardenburg syndrome type 2A (Definitive), mode of inheritance: AD
  • coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness (Strong), mode of inheritance: AR
  • renal cell carcinoma (Moderate), mode of inheritance: AD
  • coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness (Strong), mode of inheritance: AR
  • Tietz syndrome (Moderate), mode of inheritance: AD
  • Waardenburg syndrome type 2 (Supportive), mode of inheritance: AD
  • Waardenburg-Shah syndrome (Supportive), mode of inheritance: AD
  • Tietz syndrome (Supportive), mode of inheritance: AD
  • melanoma, cutaneous malignant, susceptibility to, 8 (Moderate), mode of inheritance: AD
  • coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness (Strong), mode of inheritance: AR
  • melanoma, cutaneous malignant, susceptibility to, 8 (Strong), mode of inheritance: AD
  • Waardenburg syndrome type 2A (Strong), mode of inheritance: AD
  • Waardenburg syndrome type 2 (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Waardenburg syndrome, type 2A; Tietz albinism-deafness syndrome; Coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness (COMMAD); Melanoma, cutaneous malignant, susceptibility to, 8; Renal cell carcinoma with or without malignant melanomaADAudiologic/Otolaryngologic; OncologicFor Waardenburg syndrome, type 2A, Tietz albinism-deafness syndrome, and COMMAD, early recognition and treatment of hearing impairment may improve outcomes, including speech and language development; For Melanoma, cutaneous malignant, susceptibility to and Renal cell carcinoma with or without malignant melanoma, awareness may allow preventive measures, surveillance, and early diagnosis and treatment of diseaseAudiologic/Otolaryngologic; Craniofacial; Dermatologic; Musculoskeletal; Ophthalmologic; Oncologic13985019; 5006208; 331943; 666627; 7951321; 7874167; 7702105; 7573125; 8589691; 9158138; 10851256; 18510545; 20024939; 22012259; 22080950; 23167872; 23414473; 23774529; 23802662; 24638154; 24767713; 27889061
Digenic inheritance (with TYR) has been reported

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MITF gene.

  • Waardenburg syndrome type 2A (16 variants)
  • not provided (10 variants)
  • Tietz syndrome;Waardenburg syndrome type 2A;Melanoma, cutaneous malignant, susceptibility to, 8 (5 variants)
  • Rare genetic deafness (4 variants)
  • Waardenburg syndrome type 2A;Tietz syndrome;Melanoma, cutaneous malignant, susceptibility to, 8 (3 variants)
  • Coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness (2 variants)
  • Melanoma, cutaneous malignant, susceptibility to, 8;Tietz syndrome;Waardenburg syndrome type 2A (2 variants)
  • Waardenburg syndrome type 1 (1 variants)
  • Heterochromia iridis;Poliosis;Prelingual sensorineural hearing impairment (1 variants)
  • Melanoma, cutaneous malignant, susceptibility to, 8;Waardenburg syndrome type 2A;Tietz syndrome (1 variants)
  • Hearing impairment (1 variants)
  • Nonsyndromic genetic hearing loss (1 variants)
  • Waardenburg syndrome (1 variants)
  • Tietz syndrome (1 variants)
  • Ear malformation (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MITF gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
1
clinvar
6
clinvar
76
clinvar
2
clinvar
86
missense
1
clinvar
9
clinvar
235
clinvar
5
clinvar
1
clinvar
251
nonsense
13
clinvar
6
clinvar
1
clinvar
20
start loss
1
clinvar
1
clinvar
2
frameshift
12
clinvar
3
clinvar
1
clinvar
16
inframe indel
1
clinvar
1
clinvar
2
splice donor/acceptor (+/-2bp)
2
clinvar
8
clinvar
10
splice region
1
13
32
46
non coding
1
clinvar
59
clinvar
75
clinvar
42
clinvar
177
Total 30 29 304 156 45

Variants in MITF

This is a list of pathogenic ClinVar variants found in the MITF region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
3-69739569-C-T not specified Likely benign (Aug 15, 2023)1697576
3-69739657-G-T not specified Uncertain significance (Jun 02, 2016)505050
3-69739661-A-G MITF-related disorder Uncertain significance (Jan 03, 2024)3047368
3-69739769-C-G Likely benign (Jun 21, 2018)1195048
3-69739945-C-A Likely benign (Jun 21, 2018)1197772
3-69763693-G-T Benign/Likely benign (Jul 01, 2024)669675
3-69763752-C-T Benign (Jun 21, 2018)1291113
3-69763864-C-T Likely benign (Aug 01, 2023)2653963
3-69763889-C-G Tietz syndrome Uncertain significance (May 09, 2019)932038
3-69763911-A-G MITF-related disorder Uncertain significance (Mar 19, 2023)2628573
3-69763917-T-C not specified • Hereditary cancer-predisposing syndrome Likely benign (Jul 01, 2024)1284441
3-69763927-G-A not specified • Hereditary cancer-predisposing syndrome • MITF-related disorder Conflicting classifications of pathogenicity (Apr 15, 2021)228854
3-69763939-GA-G Uncertain significance (Jul 09, 2020)1678278
3-69794494-C-T MITF-related disorder Uncertain significance (Apr 05, 2024)3357405
3-69794509-T-C MITF-related disorder Uncertain significance (Aug 18, 2023)2631055
3-69866298-C-T not specified Likely benign (Jun 29, 2015)227547
3-69866302-T-C MITF-related disorder Likely benign (Dec 09, 2019)3048546
3-69866343-A-G MITF-related disorder Uncertain significance (Oct 30, 2023)3048249
3-69866345-C-T not specified Uncertain significance (Oct 18, 2016)505334
3-69879094-T-C not specified Likely benign (Aug 15, 2023)1697577
3-69879137-T-G MITF-related disorder Uncertain significance (Aug 18, 2023)2631029
3-69879140-C-T MITF-related disorder Likely benign (Jun 06, 2023)3055283
3-69879143-C-T not specified Likely benign (Nov 24, 2014)929971
3-69879170-G-A MITF-related disorder Likely benign (Jun 02, 2022)3051214
3-69879170-G-T MITF-related disorder Likely benign (Mar 27, 2019)3047190

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MITFprotein_codingprotein_codingENST00000352241 10228903
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.9810.0188125704041257080.0000159
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.472433170.7680.00001873439
Missense in Polyphen66119.390.55281263
Synonymous0.3591161210.9580.00000772977
Loss of Function4.38429.80.1340.00000191289

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.0001090.000109
Finnish0.000.00
European (Non-Finnish)0.00001770.0000176
Middle Eastern0.0001090.000109
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transcription factor that regulates the expression of genes with essential roles in cell differentiation, proliferation and survival. Binds to M-boxes (5'-TCATGTG-3') and symmetrical DNA sequences (E-boxes) (5'-CACGTG-3') found in the promoters of target genes, such as BCL2 and tyrosinase (TYR). Plays an important role in melanocyte development by regulating the expression of tyrosinase (TYR) and tyrosinase-related protein 1 (TYRP1). Plays a critical role in the differentiation of various cell types, such as neural crest-derived melanocytes, mast cells, osteoclasts and optic cup-derived retinal pigment epithelium. {ECO:0000269|PubMed:10587587, ECO:0000269|PubMed:22647378, ECO:0000269|PubMed:27889061, ECO:0000269|PubMed:9647758}.;
Disease
DISEASE: Waardenburg syndrome 2A (WS2A) [MIM:193510]: WS2 is a genetically heterogeneous, autosomal dominant disorder characterized by sensorineural deafness, pigmentary disturbances, and absence of dystopia canthorum. The frequency of deafness is higher in WS2 than in WS1. {ECO:0000269|PubMed:28236341, ECO:0000269|PubMed:8589691}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Waardenburg syndrome 2, with ocular albinism, autosomal recessive (WS2-OA) [MIM:103470]: A disorder characterized by the association of features typical of Waardenburg syndrome type 2 with ocular albinism. Patients manifest reduced visual acuity, albinotic fundus, deafness, hypomelanosis. {ECO:0000269|PubMed:9647758}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Tietz albinism-deafness syndrome (TADS) [MIM:103500]: An autosomal dominant disorder characterized by generalized hypopigmentation and congenital, bilateral, profound sensorineural deafness. {ECO:0000269|PubMed:10851256}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Melanoma, cutaneous malignant 8 (CMM8) [MIM:614456]: A malignant neoplasm of melanocytes, arising de novo or from a pre- existing benign nevus, which occurs most often in the skin but also may involve other sites. {ECO:0000269|PubMed:22012259, ECO:0000269|PubMed:22080950}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness (COMMAD) [MIM:617306]: An autosomal recessive syndrome characterized by severe microphthalmia, profound congenital sensorineural hearing loss, lack of pigment in the hair, skin, and eyes, macrocephaly, facial dysmorphism, and osteopetrosis. {ECO:0000269|PubMed:27889061}. Note=The disease is caused by mutations affecting the gene represented in this entry. An allelic combination involving at least one dominant-negative mutation, inherited in a recessive manner, represents the underlying molecular mechanism leading to COMMAD syndrome. {ECO:0000269|PubMed:27889061}.; DISEASE: Note=Variations affecting this gene are associated with susceptibility to pheochromocytomas and paragangliomas, rare neural crest-derived tumors with an approximate incidence of 1:300,000/year. {ECO:0000269|PubMed:27680874}.;
Pathway
Melanoma - Homo sapiens (human);Mitophagy - animal - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human);Osteoclast differentiation - Homo sapiens (human);Melanogenesis - Homo sapiens (human);RANKL-RANK (Receptor activator of NFKB (ligand)) Signaling Pathway;Neural Crest Differentiation;Kit receptor signaling pathway;Prostaglandin Synthesis and Regulation;melanocyte development and pigmentation pathway;SUMOylation of transcription factors;Post-translational protein modification;SUMO E3 ligases SUMOylate target proteins;Metabolism of proteins;KitReceptor;SUMOylation;Regulation of nuclear beta catenin signaling and target gene transcription;Signaling mediated by p38-alpha and p38-beta;Signaling events mediated by Stem cell factor receptor (c-Kit);Regulation of retinoblastoma protein;IL6-mediated signaling events (Consensus)

Recessive Scores

pRec
0.423

Intolerance Scores

loftool
0.203
rvis_EVS
-0.56
rvis_percentile_EVS
19.73

Haploinsufficiency Scores

pHI
0.851
hipred
Y
hipred_score
0.825
ghis
0.562

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.944

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Mitf
Phenotype
vision/eye phenotype; limbs/digits/tail phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; pigmentation phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; growth/size/body region phenotype; hematopoietic system phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype;

Zebrafish Information Network

Gene name
mitfa
Affected structure
iridophore
Phenotype tag
abnormal
Phenotype quality
increased amount

Gene ontology

Biological process
negative regulation of transcription by RNA polymerase II;transcription, DNA-templated;regulation of transcription, DNA-templated;positive regulation of gene expression;osteoclast differentiation;melanocyte differentiation;negative regulation of cell migration;regulation of cell population proliferation;camera-type eye development;canonical Wnt signaling pathway involved in negative regulation of apoptotic process;cell fate commitment;regulation of osteoclast differentiation;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;bone remodeling;protein-containing complex assembly;positive regulation of DNA-templated transcription, initiation;regulation of RNA biosynthetic process
Cellular component
nucleus;nucleoplasm;protein-containing complex
Molecular function
RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;chromatin binding;protein binding;protein dimerization activity;E-box binding